Sign In
Buy GSK
$51.53
+0.0200 (+0.0388%)
At Close: Aug 04, 2026
GSK slide wipes £2.5bn off its market value, but for one broker this puts the stock in bargain basement territory
10:31am, Monday, 07'th Nov 2022
City broker Shore Capital remained upbeat on the prospects for shares in GSK PLC (LSE:GSK, NYSE:GSK) in spite of the failure of a key clinical trial for a new bone marrow cancer drug. It repeated its
GSK loses almost £1.7bn value after drug trial failure
03:31am, Monday, 07'th Nov 2022
Almost £1.7bn was wiped from the value of GSK PLC (LSE:GSK, NYSE:GSK) in opening deals after the drug developer revealed a late-stage study failed to meet its main goal. Blenrep was deemed no better
Vanguard Health Care Fund Exits Viatris, Plugs Into GSK in 3rd Quarter
06:12pm, Friday, 04'th Nov 2022
The Vanguard Health Care Fund (Trades, Portfolio) disclosed in a regulatory filing that its top trades during the third quarter included the closure of its positions in Viatris Inc. ( VTRS , Financial
GSK's new antibiotic a handy add-on, suggests Deutsche Bank
12:33pm, Friday, 04'th Nov 2022
GSK's experimental fluoroquinolone antibiotic gepotidacin ended its trial early due to its success in treating uncomplicated urinary tract infections (UTIs), the pharma announced this week. Deutsche B
Vir Obliterates Quarterly Sales Expectations As Covid Drug Delivers Triple-Digit Growth
11:34am, Friday, 04'th Nov 2022
Vir Biotechnology obliterated expectations for its Covid drug in the third quarter, and Vir stock leaped above its 200-day line. The post Vir Obliterates Quarterly Sales Expectations As Covid Drug Del
GSK to submit urinary infection treatment for approval after trial success
04:29am, Thursday, 03'rd Nov 2022
GSK PLC (LSE:GSK, NYSE:GSK) said it was calling an early halt to trials of a new treatment for uncomplicated urinary tract infection (uUTI) because it has already proved its efficacy. An Independent D
GSK vaccine for older adults granted FDA priority review
05:01pm, Wednesday, 02'nd Nov 2022
GSK reported strong third-quarter earnings and raised its forecast for 2022. However worries about Zantac litigation kept investors on edge.
GSK's Q3 Earnings Beat, Ups 2022 Sales Outlook, Stock Up
02:18pm, Wednesday, 02'nd Nov 2022
GSK's (GSK) revenues benefit from the strong growth in sales across all segments. The company raises the full-year sales guidance for all its segment
GSK plc (GSK) Q3 2022 Earnings Call Transcript
02:08pm, Wednesday, 02'nd Nov 2022
GSK plc (NYSE:GSK ) Q3 2022 Earnings Conference Call November 2, 2022 8:00 AM ET Company Participants Nick Stone - Head, Global Investor Relations Emma Walmsley - CEO & Director Tony Wood - Chief Scie
GSK Surges As Shingles Vaccine Drives Commanding Third-Quarter Beat
09:31am, Wednesday, 02'nd Nov 2022
GSK stock jumped Wednesday after the company beat third-quarter forecasts due to strength from specialty medicines and Shingrix. The post GSK Surges As Shingles Vaccine Drives Commanding Third-Quarter
GSK results top City forecasts, UBS sees consensus EPS forecasts rising 3%
08:48am, Wednesday, 02'nd Nov 2022
GSK PLC (LSE:GSK, NYSE:GSK)'s third quarter results beat City expectations according to broker UBS which said turnover of £7,829mln was 7% ahead of consensus with adjusted operating profit of £2,605
GSK (GSK) Q3 Earnings and Revenues Beat Estimates
08:17am, Wednesday, 02'nd Nov 2022
Glaxo (GSK) delivered earnings and revenue surprises of 21.11% and 18.99%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
GSK Raises Guidance as Earnings Beat Helps Sure Up Position of CEO
06:01am, Wednesday, 02'nd Nov 2022
GSK became a pure-play pharmaceutical company after spinning off its consumer-health arm earlier this year.
GSK lifts guidance again as bumper third quarter results top City forecasts
04:05am, Wednesday, 02'nd Nov 2022
GSK raised its full year guidance for the second time in three months as soaring sales of its shingles vaccine, Shingrix, drove bumper third quarter results which comfortably topped City expectations.
GSK lifts 2022 view after third quarter sales of $8.99 billion beat forecasts
04:02am, Wednesday, 02'nd Nov 2022
GSK PLC on Wednesday raised its guidance for the full year and posted rising sales for the third quarter that beat expectations.
